GTS-21

GTS-21 (DMXB-A) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It binds to both the α4β2 and α7 subtypes, but only activates the α7 to any significant extent.

Both GTS-21 itself and its demethylated active metabolite 4-OH-GTS-21 display nootropic and neuroprotective effects,   and GTS-21 is being investigated for the treatment of Alzheimer's disease, nicotine dependence, and most importantly for schizophrenia.